公开(公告)号：US20220177884A1

公开(公告)日：2022-06-09

申请号：US17581855

申请日：2022-01-21

申请人： HOFFMANN-LA ROCHE INC.

发明人： Peter HAGEDORN ,  Anja Mølhart HØG ,  Marianne L. JENSEN ,  Richard E. OLSON

IPC分类号： C12N15/113

摘要： The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.

公开(公告)号：US20210123054A1

公开(公告)日：2021-04-29

申请号：US17139161

申请日：2020-12-31

申请人： Hoffmann-La Roche Inc.

发明人： Peter HAGEDORN ,  Anja Mølhart HØG ,  Richard E. OLSON ,  Marianne L. JENSEN

IPC分类号： C12N15/113

摘要： The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.

公开(公告)号：US20200010831A1

公开(公告)日：2020-01-09

申请号：US16503340

申请日：2019-07-03

申请人： Hoffmann-La Roche, Inc.

发明人： Peter HAGEDORN ,  Anja Mølhart HØG ,  Marianne L. JENSEN ,  Richard E. Olson

IPC分类号： C12N15/113

摘要： The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.